LGALS3 and neoplasm: Gal-3 knockdown enhanced the sensitivity of tumor cells to the apoptotic agent arsenic trioxide (ATO, which is already approved by the US Food and Drug Administration for the treatment of acute myeloid leukemia) [19], making Gal-3 an interesting therapeutic target.